MedTrace Logo

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

NCT03677401 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 295

Last updated 2021-05-20

Study results available
· View outcomes & findings →

Summary

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Conditions

Interventions

DRUG

5mg Serlopitant Tablets

Serlopitant Tablets

DRUG

Placebo Tablets

Placebo Tablets

Sponsors & Collaborators

  • Vyne Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Sonja Stander, MD · Universitätsklinikum Münster Klinik für Hautkrankheiten Zentrale Studienkoordination für innovative Dermaologie (ZID)

  • Jacek Szepietowski, MD, Ph.D · Lukasz Matusiak 4HEALTH

  • Franz Josef Legat, MD · Medizinische Universität Graz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-29
Primary Completion
2020-01-09
Completion
2020-02-06
FDA Drug
Yes

Countries

  • Austria
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677401 on ClinicalTrials.gov